Role of EGFR TKIs in uncommon and compound mutations

Many uncommon and compound mutations are oncogene-drivers that may be targets for NSCLC therapy. In this DIALOG webinar, Dr. Satoru Miura (Japan) explores the role of EGFR TKI therapy in the treatment of NSCLC with uncommon or compound mutations.

About the speaker

Professor Satoru Miura is the Chief physician in Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata City, Japan. He is a Board-Certified Senior Member of Japanese Society of Medical Oncology and a Board Member of Lung Cancer Study Group in Japan Clinical Oncology Group. He is also a member of the Guideline Control Committee Member of the Japan Lung Cancer Society (Chemotherapy and Multidisciplinary Treatment).

Estimated Time of Completion: 11 mins.